![Two men, seated indoors around a table, engaged in a conversation and playing chess Two men, seated indoors around a table, engaged in a conversation and playing chess](/sites/novartis_com/files/styles/cards_1_3/public/2023-11/young-and-senior-men-playing-chess-and-laughing.jpg.webp?itok=qlEDLubb)
Discover our medicines
Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
![A female research scientist in a lab looking at a sample A female research scientist in a lab looking at a sample](/sites/novartis_com/files/styles/cards_1_3/public/2023-11/portrait-research-scientist-cambridge.jpg.webp?itok=XGxCz1ar)
Explore our science
Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
![Group of warm clothed women, seated outside, smiling and laughing Group of warm clothed women, seated outside, smiling and laughing](/sites/novartis_com/files/styles/cards_1_3/public/2023-11/group-of-warm-clothed-people-smilling-and-laughing.jpg.webp?itok=wVBQo2cD)
Learn about our impact
Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective.
![Novartis is an official partner of the Eurovision Song Contest 2025 Novartis is an official partner of the Eurovision Song Contest 2025](/sites/novartis_com/files/styles/cta_image/public/2024-10/novartis-basel-eurovision-partnership.jpg.webp?itok=QjgsVT7v)
Official partner of the Eurovision Song Contest 2025
We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
![Q3 2024 Q3 2024](/sites/novartis_com/files/styles/cta_image/public/2024-10/q3-2024-media-content.jpg.webp?itok=qKxVa0EU)
Novartis Financial Results – Q3 2024
Novartis announced the company’s financial results for the third quarter of 2024.
Latest news
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
![Shanelle Gabriel spending time with her father in New York Shanelle Gabriel spending time with her father in New York](/sites/novartis_com/files/styles/cta_image/public/2024-01/shanelle-gabriel-sitting-on-bench-with-her-father-new-york.jpg.webp?itok=kGsAkDwD)
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.